| Identification | Back Directory | [Name]
GLP-1(7-37)Acetate | [CAS]
1450806-98-0 | [Synonyms]
GLP-1(7-37)Acetate
GLP-1(7-37) acetate(106612-94-6 free base)
Inhibitor,inhibit,GCGR,Glucagon Receptor,GLP1(737) acetate(106612946 free base),GLP 1(7 37) acetate(106612 94 6 free base) | [Molecular Formula]
C153H232N40O49 | [MDL Number]
MFCD16876067 | [MOL File]
1450806-98-0.mol | [Molecular Weight]
3415.77 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [color ]
White to off-white | [Sequence]
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly | [InChIKey]
YJIJUMYAXDUEKM-BVNXRIOCNA-N |
| Hazard Information | Back Directory | [Description]
GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion[1].
GLP-1(7-37) (0.5, 5 or 50 pmol/min/kg) infused during the second hour of a 2-hour 11-mM hyperglycemic clamp produces a dose-related enhancement of the glucose-stimulated increase in plasma insulin concentration and an increased rate of glucose infusion in rats[2].Infusion of GLP-1(7-37) (5 pmol/min/kg) from 1 hour through 7 hours produces a sustained increase in plasma insulin concentration relative to levels in rats infused with vehicle in rats with maintained glucose concentration at 11 mM[2]. Animal Model: Male Sprague-Dawley rats weighing 300 to 350 g with glucose IV at a variablerate for 7 hours to maintain plasma glucose concentration at 11 mM[2]. | [Uses]
GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion[1]. | [in vivo]
GLP-1(7-37) (0.5, 5 or 50 pmol/min/kg) infused during the second hour of a 2-hour 11-mM hyperglycemic clamp produces a dose-related enhancement of the glucose-stimulated increase in plasma insulin concentration and an increased rate of glucose infusion in rats[2].
Infusion of GLP-1(7-37) (5 pmol/min/kg) from 1 hour through 7 hours produces a sustained increase in plasma insulin concentration relative to levels in rats infused with vehicle in rats with maintained glucose concentration at 11 mM[2].
| Animal Model: | Male Sprague-Dawley rats weighing 300 to 350 g with glucose IV at a variable
rate for 7 hours to maintain plasma glucose concentration at 11 mM[2].
| | Dosage: | 5 pmol/min/kg. | | Administration: | IV from 1 hour through 7 hours[2]. | | Result: | Produced a sustained increase in plasma insulin concentration relative to levels in rats infused with vehicle. |
| Animal Model: | Male Sprague-Dawley rats weighing 300 to 350 g with maintained plasma glucose concentration at 11 mM[2].
| | Dosage: | 0.5, 5 or 50 pmol/min/kg. | | Administration: | IV during the second hour of a 2-hour 11-mmol/L hyperglycemic clamp. | | Result: | Produced a dose-related enhancement of the glucose-stimulated increase in plasma insulin concentration and an increased rate of glucose infusion. |
| [storage]
Store at -20°C | [References]
[1]. Sarrauste de Menthiere, C. et al. Structural requirements of the N-terminal region of GLP-1-[7-37]-NH2 for receptor interaction and cAMP production. European journal of medicinal chemistry 39, 473-480, doi:10.1016/j.ejmech.2004.02.002 (2004).
[2]. Hargrove DM, et al. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. Metabolism. 1995 Sep;44(9):1231-7. |
|
| Company Name: |
Phygene Gold
|
| Tel: |
18059081430 |
| Website: |
www.phygene.com/ |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|